| Literature DB >> 31620233 |
Niranjan Thota1, Parameshwar Makam1, Kamal K Rajbongshi1, Savania Nagiah2, Naeem Sheik Abdul2, Anil A Chuturgoon2, Amit Kaushik3, Gyanu Lamichhane3, Anou M Somboro4, Hendrik G Kruger1, Thavendran Govender5, Tricia Naicker1, Per I Arvidsson1,6.
Abstract
Herein we demonstrate the expanded utility of a recently described N-trifluoromethylthiolation protocol to sulfonimidamide containing substances. The novel N-trifluoromethylthio sulfonimidamide derivatives thus obtained were evaluated for antibacterial activity against Mycobacterium tuberculosis (M. tb.) and Mycobacterium abscessus and Gram + Ve (Streptococcus aureus, Bacillus subtilis), and Gram - Ve (Escherichia coli, Pseudomonas aeruginosa) bacteria. Two compounds, 13 and 15 showed high antimycobacterial activity with MIC value of 4-8 μg/mL; i.e. comparable to WHO recommended first line antibiotic for TB infection ethambutol. The same compounds were also found to be cytotoxic in HepG2 cells (compound 13 IC50 = 15 μg/mL; compound 15 IC50 = 65 μg/mL). A structure activity relationship, using matched pair analysis, gave the unexpected conclusion that the trifluoromethylthio moiety was responsible for the cellular and bacterial toxicity. Given the increasing use of the trifluoromethylthio group in contemporary medicinal chemistry, this observation calls for considerations before implementation of the functionality in drug design.Entities:
Year: 2019 PMID: 31620233 PMCID: PMC6792286 DOI: 10.1021/acsmedchemlett.9b00285
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345